Search results
Results from the WOW.Com Content Network
A review of investigational antibiotics shows that several new agents will become available in the coming years, even though the pace of antimicrobial research has proven far too slow. Overuse of antimicrobial agents and problems with infection control practices have led to the development of multidrug-resistant gram-negative bacterial infections.
An antimicrobial is an agent that kills microorganisms (microbicide) or stops their growth (bacteriostatic agent). [1] Antimicrobial medicines can be grouped according to the microorganisms they act primarily against. For example, antibiotics are used against bacteria, and antifungals are used against fungi. They can also be classified ...
The multi antimicrobial extrusion protein family (MATE). [5] Of these, only the ABC superfamily are primary transporters, the rest being secondary transporters utilizing proton or sodium gradient as a source of energy. Whereas MFS dominates in Gram positive bacteria, the RND family was once thought to be unique to Gram negative bacteria.
An important structural change in the development of second generation cephalosporins was the introduction of an α-iminomethoxy group to the C-7 side chain. This gave an increased resistance to β-lactamases due to stereochemical blocking of the beta-lactam ring. Cefuroxime was the first cephalosporin to incorporate this side chain.
The antimicrobial spectrum of an antibiotic can be determined by testing its antimicrobial activity against a wide range of microbes in vitro. Nonetheless, the range of microorganisms which an antibiotic can kill or inhibit in vivo may not always be the same as the antimicrobial spectrum based on data collected in vitro. [2] [5]
The carbapenem ertapenem is one of several first-line agents recommended by the Infectious Disease Society of America for the empiric treatment of community-acquired intra-abdominal infections of mild-to-moderate severity. Agents with anti-pseudomonal activity, including doripenem, imipenem, and meropenem, are not recommended in this population ...
This is a favorable drug design over many clinically used competing agents, because most of them, such as clavulanic acid, become hydrolysed, and are therefore only useful for a finite period of time. This generally causes the need for a higher concentration of competitive inhibitor than would be necessary in an unhydrolyzable inhibitor.
A colored electron microscopy image of methicillin-resistant staphylococcus aureus (), a bacterium commonly targeted by broad-spectrum antibioticsA broad-spectrum antibiotic is an antibiotic that acts on the two major bacterial groups, Gram-positive and Gram-negative, [1] or any antibiotic that acts against a wide range of disease-causing bacteria. [2]